ADMA Biologics (ADMA) Stock Price

Financial Performance

ADMA Biologics' revenue has shown an upward trend, with a quarterly increase of 11.8% and a year-over-year increase of 62.2%, indicating a strong sales performance. Gross profit also rose by 4.1% from the previous quarter and by an impressive 93.1% YoY, suggesting improved cost management or pricing power. The company's operating income grew modestly at 1.1% QoQ but surged significantly at 178.5% YoY, reflecting operational efficiency improvements or increased sales volume.

The EBITDA ratio stands at 0.35, which may suggest moderate earnings before interest, taxes, depreciation and amortization relative to the company's total assets.

Stock Price

The stock is currently trading at $16.19 with a PE ratio of about 59.96, which might indicate that the market has high expectations for future earnings growth despite its recent downtrend (down by -12.9%). The RSI value at around 39 indicates that the stock is neither overbought nor oversold while the stock price is above its 200-day moving average ($14.74), suggesting an overall bullish trend in the medium term.

Alternative Data Signals

Website traffic trends show significant growth both MoM (21.9%) and YoY (119%), possibly indicating heightened interest in ADMA Biologics' operations or products/services from consumers or investors alike.

Social media presence shows a steady increase as Twitter followers have risen by approximately 16%. However, there was a decline in job postings (-14%) which could imply slower expansion plans or workforce consolidation efforts.

Around two-thirds of employees reported a positive business outlook, indicating a generally optimistic sentiment about the company's future prospects.

Conclusion

In conclusion, despite short-term stock price volatility, ADMA Biologics' strong financial performance and positive alternative data signals suggest a promising future. The overall analysis leans towards being bullish for ADMA Biologics' stock.

Note: This AI Stock Analysis is based on data as of January 28. Our members can refresh and get access to an up-to-date AI stock analysis.

Sign up

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of ADMA Biologics (ADMA), currently trading at $20.26, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.